Study of blinatumomab for refractory generalized myasthenia gravis
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new treatment for people with generalized myasthenia gravis (a condition causing muscle weakness) that hasn't improved with standard medications. The treatment, called blinatumomab, aims to reduce weakness by targeting certain immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with generalized myasthenia gravis (weakness affecting many muscles)
- You have tried at least two standard immunosuppressive medications and still have symptoms
- Your blood tests are positive for AChR, MuSK, or LRP4 antibodies
- You are not pregnant or breastfeeding and do not have allergies to blinatumomab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new medication called blinatumomab for people with difficult-to-treat myasthenia gravis, a condition that causes muscle weakness. The drug aims to help reduce symptoms and improve quality of life for those who haven't improved with standard treatments.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This trial tests a new cell therapy using special immune cells (CAR-NK cells) that may help people whose myasthenia gravis has not improved with standard treatments. It aims to see if these cells can reduce muscle weakness and improve daily life.
This trial tests a low-dose medication called blinatumomab (a type of immunotherapy) to see if it can help people with severe, treatment-resistant autoimmune encephalitis or autoimmune cerebellitis. It aims to calm the immune system's attack on the brain, potentially improving symptoms when standard treatments haven't worked.
This early study tests a new cell therapy (GC012F) for people with difficult-to-treat generalized myasthenia gravis. The treatment aims to reset the immune system to reduce muscle weakness.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
Hear when a new Myasthaenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.